Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of …
Celgene Corporation (NASDAQ:CELG) shares are down nearly 2% this morning, after the drug giant reported mixed first-quarter results. While Celgene reported an in-line Revlimid number, Otezla missed …
Celgene Corporation (NASDAQ:CELG) announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 …
Oppenheimer analysts are chiming in with upbeat forecasts on two biotech players: Celgene Corporation (NASDAQ:CELG) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP). One analyst is out …
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
In a research report released Thursday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …
Cantor analyst Mara Goldstein came out today with a bullish note on shares of Celgene Corporation (NASDAQ:CELG), after the pharma giant pre-announced 2016 results …
Celgene Corporation (NASDAQ:CELG) presented at JPM this morning, providing guidance updates and top-line FY2016 results. While FY2016 top-line results were slightly below expectations, …
Celgene Corporation (NASDAQ:CELG) provided a business update as well as its preliminary 2016 unaudited results and financial guidance for 2017 at the 35th …
Celgene Corporation (NASDAQ: CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending …
